You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,289,475

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,289,475

Title:	Treatment of chronic inflammatory respiratory disorders
Abstract:	This invention relates, e.g., to a method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of and/or the activity of VEGF-A and/or VEGFR1 and/or VEGFR2 and/or NP1, or a combination thereof. Also described are screening assays for agents for treating a subject having a chronic inflammatory respiratory disorder, and kits for performing one of the methods of the invention.
Inventor(s):	Kim; Jean (Baltimore, MD)
Assignee:	The Johns Hopkins University (Baltimore, MD)
Application Number:	13/127,876
Patent Claims:	1. A method for treating a human subject having chronic rhinosinusitis by inhibiting the proliferation of an epithelial cell, comprising contacting the cell with: an effective amount of an antibody or an antigen binding fragment thereof that binds to human neuropilin-1, and optionally an effective amount of an antibody or an antigen binding fragment thereof that binds to human vascular endothelial growth factor-A, and/or an effective amount of antibody or an antigen binding fragment thereof that binds to human VEGF receptor 1, and/or an effective amount of an antibody or an antigen binding fragment thereof that binds to human VEGF receptor 2. 2. The method of claim 1, wherein the epithelial cell is in said subject, and the effective amount of the antibody or an antigen binding fragment thereof is administered to said subject. 3. The method of claim 1, wherein the chronic rhinosinusitis is chronic rhinosinusitis with nasal polyposis. 4. The method of claim 1, wherein the antibody or an antigen binding fragment thereof that binds to human neuropilin-1, and antibody or an antigen binding fragment thereof that binds to human vascular endothelial growth factor-A and/or human VEGF receptor 1, and/or human VEGF receptor 2 are administered by a systemic intravenous (IV) route. 5. The method of claim 1, wherein the antibody or an antigen binding fragment thereof that binds to human neuropilin-1, and antibody or an antigen binding fragment thereof that binds to human vascular endothelial growth factor-A and/or human VEGF receptor 1, and/or human VEGF receptor 2 are administered by an intranasal route. 6. The method of claim 1, wherein the antibody or an antigen binding fragment thereof that binds to human VEGF-A is selected from the group consisting of ranibizumab and bevacizumab. 7. A method for treating a human subject having chronic rhinosinusitis with nasal polyposis comprising administering to the subject an effective amount of an antibody or an antigen binding fragment thereof that binds to human neuropilin-1.

Details for Patent 9,289,475

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2028-11-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2028-11-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2028-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.